tbuckley/cabot-search huggingface dataset:
Isolation, characterization and expansion of circulating tumor cells in solid cancers
Authors: Arutha Kulasinghe, Joanna Kapeleris, Liz Kenny, Majid Warkiani, Ian Vela, Jean-Paul Thiery, Ken O'Byrne, Chamindie Punyadeera
Journal: Cancer Research (2019)

Metastasis in cancer patients is reflected by measurable levels of circulating tumor cells (CTCs) in the blood of cancer patients. CTCs represent cancer cells from the primary and metastatic sites, thereby providing a comprehensive representation of the tumor burden of an individual patient. Recent advancements have shown that PD-1/PD-L1 immune checkpoint therapies have durable responses in a number of solid tumor types.  Our study was designed to use multiple CTC enrichment platforms for the capture of CTCs and novel culture formulations for the ex vivo expansion of CTCs. Head and Neck cancer (n=300) and lung cancer (n=80) patients were recruited to investigate the prognostic role of CTCs.  We evaluated multiple CTC isolation technologies (CellSearch, filtration, CD45 depletion, inertial microfluidics) using matched patient samples which showed that epitope-independent CTC isolation captured a greater proportion of CTCs. Molecular alterations present in the primary tissue were confirmed in the CTCs by 3D-DNA FISH (EGFR-amplification, ALK-translocations). In HNC, the presence of CTC clusters associated with the development of distant metastatic disease (P=0.0313). HNC CTC-positive patients had shorter progression free survival (PFS) (Hazard ratio [HR]: 4.946; 95% confidence internal [CI]:1.571-15.57; P=0.0063) and PD-L1-positive CTCs were found to be significantly associated with worse outcome ([HR]:5.159; 95% [CI]:1.011-26.33; P=0.0485).  In a proof of principle study, we were able to demonstrate for the first time, short-term patient derived CTC cultures outside the patient’s body from 7/18 HNC samples (4/7 HPV-positive). Recently, we have preliminary data that suggests that PD-L1 is frequently expressed on CTCs in HNC and lung cancer and an immunoscore may be able to identify patients likely to benefit from immunotherapy-a current unmet clinical need. Expanding CTCs outside the patient’s body allows for the recapitulation of the molecular diversity present within the tumor, understanding of the disease progression and testing of therapies.
Benign Symmetric Lipomatosis
Authors: David A. Strange
Journal: JAMA (1968)

<h3>To the Editor:—</h3> We read with interest the recent report by Comings and Glenchur (<b>203</b>:305, 1968), in which the authors describe a case of bilateral symmetrical involvement of the supraclavicular fossae by lipomatoses. During the past two years we have personally observed 22 individuals with this condition and are presently preparing our information for publication. We have found a high incidence of the following associated conditions: painless symmetrical enlargement of parotid glands, hypertension, diabetes, obesity, and gout. We would be interested to know whether the patient reported by Comings and Glenchur had any of these other elements, which we have come to consider to be a well-defined clinical syndrome.
PSMA Expression in the Neovasculature Associated With Rectal Adenocarcinoma
Authors: Ida Sonni, Justin Caron, Amar U. Kishan, V. Raman Muthusamy, Jeremie Calais
Journal: Clinical Nuclear Medicine (2020)

Abstract We report the case of a 63-year-old man who underwent MRI and 68 Ga-PSMA-11 PET/CT for biochemical recurrence localization after radical prostatectomy (serum PSA, 0.25 ng/mL) and describe the incidental discovery of a rectal adenocarcinoma. Immunohistochemical analysis showed PSMA staining in the tumor-associated neovasculature, but not in normal vasculature, or tumor cells. After surgical removal, he was treated with salvage radiotherapy to the postoperative prostate bed. This case example has several implications: the findings confirm the expression of PSMA in the tumor-associated neovasculature of a rectal cancer, nonprostate cancers’ stroma may represent a potentially relevant target for nuclear theranostics.
COMPLICATIONS OF ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP)
Authors: A Zazour, W Khannoussi, G Kharrasse, Z Ismaili
Journal: Endoscopy (2020)

Methods A descriptive retrospective study for 32 months, at the Mohammed VI Oujda University Hospital, which included 512 ERCP procedures. All the patients had an abdominal X-Ray at the end of the procedure and close clinical monitoring for 24 hours, with biological control. The diagnosis of post-ERCP acute pancreatitis has been made using the diagnostic criterias.
SINGLE-OPERATOR CHOLANGIOSCOPY-GUIDED ELECTROHYDRAULIC LITHOTRIPSY COMES TO RESCUE IN A DIFFICULT BILE DUCT STONE CASE
Authors: MF de Lima, N Nunes, CC Rebelo, DB Moura, VC Santos, AC Rego, JR Pereira, N Paz, MA Duarte
Journal: Endoscopy (2020)

A 27-year-old female patient presented with abdominal pain, vomiting and jaundice. She had been submitted to a subtotal cholecystectomy two years earlier. Laboratorial tests revealed an elevated total bilirubin (7.56 mg/dL, direct 6.79 mg/dL) and abdominal ultrasound showed a 10 mm common bile duct (CBD). An ERCP was performed, showing an impacted bile duct stone deforming the cystic duct insertion. After sphincterotomy, a stone removal using basket was not possible even using mechanical lithotripsy. An EPCR was repeated 4 weeks later, illustrating the same impacted stone. Single-operator cholangioscopy-guided electrohydraulic lithotripsy enabled bile duct stone clearance.
OUR EXPERIENCES WITH EUS-FNA IN PATIENTS WITH MEDIASTINAL LYMPHADENOMEGALY OF UNKNOWN-ORIGIN
Authors: D Illés, L Czakó
Journal: Endoscopy (2020)

Aims In Hungary there is limited access to perform EUS or EUS with fine-needle aspiration (FNA). Our aim was to overview the reports and the quality indicators of EUS(-FNA) interventions indicated by MLM.
HIF-dependent over-expression of CUB domain-containing protein 1 stimulates migration in clear cell renal cell carcinoma
Authors: O V Razorenova, E C Finger, R Colavitti, S B Chernikova, A D Boiko, Chan Ckf., A Krieg, B Bedogni, E LaGory, I L Weissman, M Broome-Powell, A J Giaccia
Journal: Cancer Research (2011)
Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Exacerbation Endpoints
Authors: M Bafadhel, F C Sciurba, P Paggiaro, I D Pavord, K Chapman, S W Yancey, D B Rubin, B Mayer, S S Harris, E S Bradford
Journal: American Journal of Respiratory and Critical Care Medicine (2018)
PERORAL ENDOSCOPIC MYOTOMY WITH THE HYBRIDKNIFE
Authors: F Straulino, N Reissig, A Genthner, A Eickhoff
Journal: Endoscopy (2020)

Aims The peroral endoscopic myotomy (POEM) is an established procedure in patients with achalasia. After incision of the mucosa the creation of the submucosal tunnel is a crucial step in this procedure. Therefor a repetive switch between injection and dissection is necessary. With standard devices the injection needle and the dissection knife has to be changed multiple times. The HybridKnife is an “all-in-one” device”, which can be used in all three steps (incision, dissection and myotomy) of the POEM procedure. We report our experience in POEM with the ERBE HybridKnife.
Effect of Biomechanical Footwear on Knee Pain in People With Knee Osteoarthritis
Authors: Stephan Reichenbach, David T. Felson, Cesar A. Hincapié, Sarah Heldner, Lukas Bütikofer, Armando Lenz, Bruno R. da Costa, Harald M. Bonel, Richard K. Jones, Gillian A. Hawker, Peter Jüni
Journal: JAMA (2020)

Individually calibrated biomechanical footwear therapy may improve pain and physical function in people with symptomatic knee osteoarthritis, but the benefits of this therapy are unclear.To assess the effect of a biomechanical footwear therapy vs control footwear over 24 weeks of follow-up.Randomized clinical trial conducted at a Swiss university hospital. Participants (N = 220) with symptomatic, radiologically confirmed knee osteoarthritis were recruited between April 20, 2015, and January 10, 2017. The last participant visit occurred on August 15, 2017.Participants were randomized to biomechanical footwear involving shoes with individually adjustable external convex pods attached to the outsole (n = 111) or to control footwear (n = 109) that had visible outsole pods that were not adjustable and did not create a convex walking surface.The primary outcome was knee pain at 24 weeks of follow-up assessed with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscore standardized to range from 0 (no symptoms) to 10 (extreme symptoms). The secondary outcomes included WOMAC physical function and stiffness subscores and the WOMAC global score, all ranging from 0 (no symptoms) to 10 (extreme symptoms) at 24 weeks of follow-up, and serious adverse events.Among the 220 randomized participants (mean age, 65.2 years [SD, 9.3 years]; 104 women [47.3%]), 219 received the allocated treatment and 213 (96.8%) completed follow-up. At 24 weeks of follow-up, the mean standardized WOMAC pain subscore improved from 4.3 to 1.3 in the biomechanical footwear group and from 4.0 to 2.6 in the control footwear group (between-group difference in scores at 24 weeks of follow-up, -1.3 [95% CI, -1.8 to -0.9]; P < .001). The results were consistent for WOMAC physical function subscore (between-group difference, -1.1 [95% CI, -1.5 to -0.7]), WOMAC stiffness subscore (between-group difference, -1.4 [95% CI, -1.9 to -0.9]), and WOMAC global score (between-group difference, -1.2 [95% CI, -1.6 to -0.8]) at 24 weeks of follow-up. Three serious adverse events occurred in the biomechanical footwear group compared with 9 in the control footwear group (2.7% vs 8.3%, respectively); none were related to treatment.Among participants with knee pain from osteoarthritis, use of biomechanical footwear compared with control footwear resulted in an improvement in pain at 24 weeks of follow-up that was statistically significant but of uncertain clinical importance. Further research would be needed to assess long-term efficacy and safety, as well as replication, before reaching conclusions about the clinical value of this device.ClinicalTrials.gov Identifier: NCT02363712.
MICRO- AND MACROFLUIDIC ASSAYS FOR BIOFILM FORMATION ON BILIARY STENTS: PRELIMINARY RESULTS OF A PILOT STUDY
Authors: R Rusconi, A Fugazza, A Capogreco, A Bruno, C Cardenas, M Piergiovanni, G Dubini, S Carrara, R Maselli, A Anderloni, A Repici
Journal: Endoscopy (2020)

Aims Data on biofilm formation and basic mechanisms of stent occlusion in function of different type of stents are lacking. The aim of this study was to investigate biofilm formation in two model assays which reproduce two fundamental physical features of the stents: geometry and fluid flow.
Risk for Occupational Transmission of Human Immunodeficiency Virus Type 1 (HIV-1) Associated with Clinical Exposures
Authors: David K. Henderson, Barbara J. Fahey, Mary Willy, James M. Schmitt, Kathleen Carey, Deloris E. Koziol, H. Clifford Lane, Joan Fedio, Alfred J. Saah
Journal: Annals of Internal Medicine (2020)

Objectives: To summarize the results of a 6-year, ongoing, prospective study of the risk for human immunodeficiency virus type 1 (HIV-1) transmission among health care workers, and to estimate the ...
ANALYSIS OF ATYPICAL SCAR PATTERNS AFTER GASTRIC ENDOSCOPIC SUBMUCOSAL DISSECTION
Authors: BJ Kim, B Kim, H Choi, JG Kim
Journal: Endoscopy (2020)

Aims Endoscopic submucosal dissection (ESD) for gastric neoplasms is a widely performed procedure. While incidences of local recurrence are rare, various post-ESD scars are encountered during follow-up endoscopy. Therefore, we investigated atypical scar patterns and evaluated the factors associated with such a condition.
WHEN NATURE TRIES TO FIND ITS WAY: AN UNUSUAL CASE OF CHOLEDOCHO-DUODENAL FISTULA COMPLICATING A “DIFFICULT” CHOLEDOCHOLITHIASIS
Authors: RD Mitri, D Scimeca, A Bonaccorso, ML Mastro, E Conte, G Russo, F Mocciaro
Journal: Endoscopy (2020)

During ERCP for choledocholitiasis, we found a bulging near the major papilla, with an orifice draining bile, suspected for biliary fistula. Contrast-medium injection through the orifice showed a stone impacted behind the duodenal wall, in a false lumen communicating with CBD by fistulous tract; CBD was occupied by multiple large stones.
The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation
Authors: Janis M Taube, Guray Akturk, Michael Angelo, Elizabeth L Engle, Sacha Gnjatic, Shirley Greenbaum, Noah F Greenwald, Cyrus V Hedvat, Travis J Hollmann, Jonathan Juco, Edwin R Parra, Marlon C Rebelatto, David L Rimm, Jaime Rodriguez-Canales, Kurt A Schalper, Edward C Stack, Cláudia S Ferreira, Konstanty Korski, Ana Lako, Scott J Rodig, Emanuel Schenck, Keith E Steele, Michael J Surace, Michael T Tetzlaff, Katharina von Loga, Ignacio I Wistuba, Carlo B Bifulco
Journal: Journal for ImmunoTherapy of Cancer (2020)

Objectives The interaction between the immune system and tumor cells is an important feature for the prognosis and treatment of cancer. Multiplex immunohistochemistry (mIHC) and multiplex immunofluorescence (mIF) analyses are emerging technologies that can be used to help quantify immune cell subsets, their functional state, and their spatial arrangement within the tumor microenvironment. Methods The Society for Immunotherapy of Cancer (SITC) convened a task force of pathologists and laboratory leaders from academic centers as well as experts from pharmaceutical and diagnostic companies to develop best practice guidelines for the optimization and validation of mIHC/mIF assays across platforms. Results Representative outputs and the advantages and disadvantages of mIHC/mIF approaches, such as multiplexed chromogenic IHC, multiplexed immunohistochemical consecutive staining on single slide, mIF (including multispectral approaches), tissue-based mass spectrometry, and digital spatial profiling are discussed. Conclusions mIHC/mIF technologies are becoming standard tools for biomarker studies and are likely to enter routine clinical practice in the near future. Careful assay optimization and validation will help ensure outputs are robust and comparable across laboratories as well as potentially across mIHC/mIF platforms. Quantitative image analysis of mIHC/mIF output and data management considerations will be addressed in a complementary manuscript from this task force.
22G Acquire vs. 20G Procore needle for endoscopic ultrasound-guided biopsy of pancreatic masses: a randomized study comparing histologic sample quantity and diagnostic accuracy
Authors: David Karsenti, Laurent Palazzo, Bastien Perrot, Jacqueline Zago, Anne-Isabelle Lemaistre, Jérôme Cros, Bertrand Napoléon
Journal: Endoscopy (2020)

Abstract Background Endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) has been suggested for obtaining high quality tissue samples from pancreatic tumors. We performed a multicenter randomized crossover trial comparing EUS-FNB with a 20G Procore needle vs. a 22G Acquire needle. The aims were to compare the quantity of targeted tissue (pancreas) and diagnostic accuracy for the two needles. Methods 60 patients admitted for EUS-FNB in three endoscopy units were included. One pass was performed consecutively with each needle, in a randomized order. Histologic material was studied in a blinded manner with respect to the needle. The primary end point was mean cumulative length of tissue core biopsies per needle pass. Results Final diagnosis was adenocarcinoma (n = 46; 77 %), neuroendocrine neoplasm (n = 11; 18 %), autoimmune pancreatitis (n = 2), and mass-forming chronic pancreatitis (n = 1). The mean cumulative length of tissue core biopsies per needle pass was significantly higher with the 22G Acquire needle at 11.4 mm (95 % confidence interval [CI] 9.0 – 13.8] vs. 5.4 mm (95 %CI 3.8 – 7.0) for the 20G Procore needle (P &lt; 0.001), as was the mean surface area (3.5 mm2 [95 %CI 2.7 – 4.3] vs. 1.8 mm2 [95 %CI 1.2 – 2.3]; P &lt; 0.001). Diagnostic adequacy and accuracy were 100 % and 87 % with the 22G Acquire needle, and 82 % and 67 % with the 20G Procore needle (P = 0.001 and P = 0.02, respectively). Conclusions EUS-guided biopsy of pancreatic masses with the 22G Acquire needle provided more tissue for histologic evaluation and better diagnostic accuracy than the 20G Procore needle.
LOW-GRADE DYSPLASIA IN BARRETT’S ESOPHAGUS IS DOWNGRADED IN HALF OF THE CASES AFTER SYSTEMATIC EXPERT PATHOLOGY REVIEW BEFORE PATIENT REFERRAL FOR ENDOSCOPIC TREATMENT
Authors: P Leclercq, G De Hertogh, R Bisschops
Journal: Endoscopy (2020)

Aims The aim of this study was to document the discrepancy between expert and community pathologists in grading Barrett´s esophagus (BE) dysplasia before patient referral for endoscopic treatment.
Case 17-2020: A 68-Year-Old Man with Covid-19 and Acute Kidney Injury
Authors: Meghan E Sise, Meridale V Baggett, Jo-Anne O Shepard, Jacob S Stevens, Eugene P Rhee
Journal: New England Journal of Medicine (2020)

A Man with Covid-19 and Acute Kidney Injury A 68-year-old man was admitted to the hospital with fever, shortness of breath, and acute kidney injury. Testing of a nasopharyngeal swab for SARS-CoV-2 ...
Unexpected Resolution of a Symptomatic Tarlov Cyst Following Hysterectomy
Authors: Asad M. Lak, Hasan A. Zaidi, Omar Arnaout
Journal: JAMA Neurology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Short-Course External Beam Radiotherapy Versus Brachytherapy for Palliation of Dysphagia in Esophageal Cancer: A Matched Comparison of Two Prospective Trials
Authors: Paul M. Jeene, Bram D. Vermeulen, Tom Rozema, Pètra M. Braam, Irene Lips, Karin Muller, Daphne van Kampen, Marjolein Y.V. Homs, Vera Oppedijk, Maaike Berbée, Peter S.N. van Rossum, Sherif el Sharouni, Peter D. Siersema, Maarten C.C.M. Hulshof
Journal: Journal of Thoracic Oncology (2020)

Short-course external beam radiotherapy (EBRT) and intraluminal brachytherapy are both accepted treatments for the palliation of dysphagia in patients with incurable esophageal cancer. We compared the effects of both treatments from two prospective studies.We performed a multicenter prospective cohort study of patients with metastasized or otherwise incurable esophageal cancer requiring palliation of dysphagia from September 2016 to March 2019. Patients were treated with EBRT in five fractions of 4 Gy. Data were compared with all patients treated with a single brachytherapy dose of 12 Gy in the SIREC (Stent or Intraluminal Radiotherapy for inoperable Esophageal Cancer) trial, both between the original cohorts and between 1:1 propensity score-matched cohorts. The primary end point was an improvement of dysphagia at 3 months without reintervention. The secondary end points included toxicity and time-to-effect.A total of 115 patients treated with EBRT and 93 patients who underwent brachytherapy were eligible for analysis. In the original cohorts, dysphagia improved after EBRT in 79% of patients compared with 64% after brachytherapy (p = 0.058). Propensity score matching resulted in 69 patients in each cohort well-balanced at baseline. Improvement of dysphagia was observed in 83% after EBRT versus 64% after brachytherapy (p = 0.048). In responding patients, improvement of dysphagia at 2 weeks was observed in 67% after EBRT compared with 35% after brachytherapy, and the maximum effect was reached after 4 weeks in 55% and 33%, respectively. Severe toxicity occurred in 3% of patients after EBRT compared with 13% after brachytherapy.Short-course EBRT appears at least as effective as brachytherapy in the palliation of dysphagia in patients with esophageal cancer.
RECENT UPPER GASTROINTESTINAL ENDOSCOPY QUALITY MEASURES SEEM TO BE USEFUL BUT NEED FURTHER VALIDATION. A MULTICENTER OBSERVATIONAL STUDY
Authors: M Romańczyk, B Ostrowski, T Romańczyk, T Marek, M Błaszczyńska, M Koziej, M Waluga, M Hartleb
Journal: Endoscopy (2020)

Aims The proper visualization and image interpretation are the key factors of good Esophagogastrodudenoscopy (EGD) quality. Nevertheless, the proper quality indicators were not yet validated for EGD. Recently two metrics were proposed: composite detection rate (CDR - the sum of gastric inlet patch, gastric polyps and duodenal bulb deformations detection rates) and endoscopist biopsy rate (EBR) that in university endoscopy units corresponds with higher gastric premalignant lesions detection and lower gastric cancers miss rate. The aim of the study was to verify these metrics among different endoscopy units settings.
PIXEL VS PATCH-BASED DEEP LEARNING MODELS, PAVING THE WAY TOWARDS REAL-TIME AI-ASSISTED DETECTION OF BARRETT’S NEOPLASIA
Authors: M Abdelrahim, M Saiko, Y Masaike, S Arndtz, E Hossain, P Bhandari
Journal: Endoscopy (2020)

Aims Early detection of Barrett’s neoplasia is challenging. Deep learning (DL) is proposed to play a role, with limited recent reports showing encouraging results. However, comparative data on the best methods to develop and implement this technology is lacking. We aim to compare two different DL models for detection of Barrett’s neoplasia, a classical patch-based, and a pixel-based model.
LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer
Authors: Xi Jin, Li-Ping Ge, Da-Qiang Li, Zhi-Ming Shao, Gen-Hong Di, Xiao-En Xu, Yi-Zhou Jiang
Journal: Molecular Cancer (2020)

Estrogen receptor-positive (ER+) breast cancers represent approximately two-thirds of all breast cancers and have a sustained risk of late disease recurrence. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have shown significant efficacy in ER+ breast cancer. However, their effects are still limited by drug resistance. In this study, we aim to explore the role of long noncoding RNA TROJAN in ER+ breast cancer.The expression level of TROJAN in breast cancer tissue and cell lines was determined by quantitative real-time PCR. In vitro and in vivo assays as well as patient derived organoid were preformed to explore the phenotype of TROJAN in ER+ breast cancer. The TROJAN-NKRF-CDK2 axis were screened and validated by RNA pull-down, mass spectrometry, RNA immunoprecipitation, microarray, dual-luciferase reporter and chromatin immunoprecipitation assays.Herein, we showed that TROJAN was highly expressed in ER+ breast cancer. TROJAN promoted cell proliferation and resistance to a CDK4/6 inhibitor and was associated with poor survival in ER+ breast cancer. TROJAN can bind to NKRF and inhibit its interaction with RELA, upregulating the expression of CDK2. The inhibition of TROJAN abolished the activity of CDK2, reversing the resistance to CDK4/6 inhibitor. A TROJAN antisense oligonucleotide sensitized breast cancer cells and organoid to the CDK4/6 inhibitor palbociclib both in vitro and in vivo.TROJAN promotes ER+ breast cancer proliferation and is a potential target for reversing CDK4/6 inhibitor resistance.